- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06465316
Prueba de teclistamab (TECVAYLI) en combinación con iberdomida para el mieloma múltiple difícil de tratar
Un ensayo de fase 1b de teclistamab en combinación con iberdomida para el mieloma múltiple en recaída o refractario
This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to survive. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as teclistamab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving iberdomide in combination with teclistamab may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma.
Descripción general del estudio
Estado
Descripción detallada
PRIMARY OBJECTIVE:
I. Estimate the recommended phase 2 dose (RP2D) of iberdomide in combination with teclistamab.
SECONDARY OBJECTIVES:
I. To evaluate the safety and toxicity profile of iberdomide in combination with teclistamab.
II. To observe and record antitumor activity.
CORRELATIVE OBJECTIVES:
I. To evaluate the changes in the tumor immune microenvironment (exhausted T-cell phenotypes, percent T regulatory cells [T regs], T-cell activation) in peripheral blood and bone marrow caused by the addition of iberdomide to teclistamab and how they relate to minimal residual disease (MRD) status, responses rates and survival outcomes.
II. To evaluate soluble B-cell maturation antigen (sBCMA) levels at baseline and how they correlate to response rates and survival outcomes in patients treated with teclistamab plus iberdomide.
III. To identify the immunophenotypic and transcriptomic characterization of malignant plasma cells that are resistant to teclistamab and iberdomide.
OUTLINE: This is a dose-escalation study of iberdomide in combination with teclistamab.
Patients receive teclistamab subcutaneously (SC) on days 1, 4, 7, 15 and 22 for cycle 1 and days 1, 8, 15 and 22 for subsequent cycles. Patients also receive iberdomide orally (PO) once daily (QD) on days 1-21 for cycle 2 and beyond. Cycles repeat every 28 days for up to 4 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood and urine sample collection, bone marrow aspiration and biopsy and positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MR) throughout the trial.
After completion of study treatment, patients are followed up every 3-6 months for up to 2 years.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85054
- Reclutamiento
- Mayo Clinic Hospital in Arizona
-
Investigador principal:
- Ricardo D. Parrondo
-
Contacto:
- Site Public Contact
- Número de teléfono: 855-776-0015
-
-
Connecticut
-
Derby, Connecticut, Estados Unidos, 06418
- Reclutamiento
- Smilow Cancer Hospital-Derby Care Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 203-785-5702
- Correo electrónico: canceranswers@yale.edu
-
Investigador principal:
- Elan Gorshein
-
Guilford, Connecticut, Estados Unidos, 06437
- Reclutamiento
- Smilow Cancer Hospital Care Center - Guilford
-
Contacto:
- Site Public Contact
- Número de teléfono: 203-785-5702
- Correo electrónico: canceranswers@yale.edu
-
Investigador principal:
- Elan Gorshein
-
New Haven, Connecticut, Estados Unidos, 06520
- Reclutamiento
- Yale University
-
Contacto:
- Site Public Contact
- Número de teléfono: 203-785-5702
- Correo electrónico: canceranswers@yale.edu
-
Investigador principal:
- Elan Gorshein
-
North Haven, Connecticut, Estados Unidos, 06473
- Reclutamiento
- Yale-New Haven Hospital North Haven Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 203-785-5702
- Correo electrónico: canceranswers@yale.edu
-
Investigador principal:
- Elan Gorshein
-
Torrington, Connecticut, Estados Unidos, 06790
- Reclutamiento
- Smilow Cancer Hospital-Torrington Care Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 203-785-5702
- Correo electrónico: canceranswers@yale.edu
-
Investigador principal:
- Elan Gorshein
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20007
- Reclutamiento
- MedStar Georgetown University Hospital
-
Investigador principal:
- Kimberley Doucette
-
Contacto:
- Site Public Contact
- Número de teléfono: 202-444-2223
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224-9980
- Reclutamiento
- Mayo Clinic in Florida
-
Investigador principal:
- Ricardo D. Parrondo
-
Contacto:
- Site Public Contact
- Número de teléfono: 855-776-0015
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- Moffitt Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-679-0775
- Correo electrónico: ClinicalTrials@moffitt.org
-
Investigador principal:
- Ariel Grajales-Cruz
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- Reclutamiento
- University of Kansas Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 913-588-3671
- Correo electrónico: KUCC_Navigation@kumc.edu
-
Investigador principal:
- Jeries Kort
-
Overland Park, Kansas, Estados Unidos, 66211
- Reclutamiento
- University of Kansas Hospital-Indian Creek Campus
-
Contacto:
- Site Public Contact
- Número de teléfono: 913-588-3671
- Correo electrónico: KUCC_Navigation@kumc.edu
-
Investigador principal:
- Jeries Kort
-
Overland Park, Kansas, Estados Unidos, 66210
- Reclutamiento
- University of Kansas Cancer Center-Overland Park
-
Contacto:
- Site Public Contact
- Número de teléfono: 913-588-3671
- Correo electrónico: KUCC_Navigation@kumc.edu
-
Investigador principal:
- Jeries Kort
-
Westwood, Kansas, Estados Unidos, 66205
- Reclutamiento
- University of Kansas Hospital-Westwood Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 913-588-3671
- Correo electrónico: KUCC_Navigation@kumc.edu
-
Investigador principal:
- Jeries Kort
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Reclutamiento
- Mayo Clinic in Rochester
-
Investigador principal:
- Ricardo D. Parrondo
-
Contacto:
- Site Public Contact
- Número de teléfono: 855-776-0015
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Reclutamiento
- Ohio State University Comprehensive Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-293-5066
- Correo electrónico: Jamesline@osumc.edu
-
Investigador principal:
- Srinivas S. Devarakonda
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Suspendido
- University of Oklahoma Health Sciences Center
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23298
- Reclutamiento
- VCU Massey Comprehensive Cancer Center
-
Investigador principal:
- Hashim Mann
-
Contacto:
- Site Public Contact
- Número de teléfono: 804-628-6430
- Correo electrónico: CTOclinops@vcu.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Patients must have histologically or cytologically confirmed multiple myeloma (MM), as defined in the International Myeloma Working Group (IMWG) criteria
-
If patients have undergone autologous stem cell transplant (SCT), day 0 of SCT must be > 100 days to be eligible for the study
-
Patients must have had disease progression after ≥ 4 prior lines of anti-myeloma treatments including one proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib), one immunomodulatory imide drug (ImiD) (e.g., thalidomide, lenalidomide, pomalidomide [POM]), and one anti-CD38 monoclonal antibody (e.g., daratumumab, isatuximab)
-
Patients must have measurable disease, defined as:
- Serum M-protein ≥ 0.5 g/dL (≥ 5 g/L)
- Urine M-protein ≥ 200 mg/24 h
- Serum free light chain (FLC) assay: "involved" FLC level ≥ 10 mg/dL (≥ 100 mg/L) and an abnormal serum free light chain ratio (< 0.26 or > 1.65)
- Note: Patients with non-secretory disease will be allowed to participate
-
Age ≥ 18 years
- Because no dosing or adverse event data are currently available on the use of iberdomide in combination with teclistamab in patients < 18 years of age, children are excluded from this study
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60)
-
Hemoglobin ≥ 7.0 g/dL (≤ 28 days prior to registration) (Without growth factor support, blood transfusion, or platelet stimulating agents for the past 7 days, excluding erythropoietin)
-
Absolute neutrophil count ≥ 1,000/mcL (≤ 28 days prior to registration) (Without growth factor support, blood transfusion, or platelet stimulating agents for the past 7 days, excluding erythropoietin)
-
Platelets ≥ 50,000/mcL (≤ 28 days prior to registration) (Without growth factor support, blood transfusion, or platelet stimulating agents for the past 7 days, excluding erythropoietin)
-
Total bilirubin ≤ 2 x institutional upper limit of normal (ULN) (≤ 28 days prior to registration)
-
Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x institutional ULN (≤ 28 days prior to registration)
-
Estimated glomerular filtration rate (eGFR) > 30 mL/min (≤ 28 days prior to registration)
-
Spot urine (albumin/creatine ratio) ≤ 500mg/g (56 mg/mmol) OR urine dipstick negative/trace (if > 1+ only eligible if confirmed ≤ 500 mg/g [56 mg/mmol] by albumin/creatinine ratio [spot urine from first void]) (≤ 28 days prior to registration)
-
Note: Laboratory results obtained during screening should be used to determine eligibility criteria. In situations where laboratory results are outside the permitted range, the investigator may re-test the subject and the subsequent within range screening result may be used to confirm eligibility
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging done a minimum of 28 days after completion of central nervous system (CNS)-directed therapy shows no evidence of progression
-
Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better
-
Based on the mechanism of action, teclistamab may cause fetal harm when administered to a pregnant woman. Females of child-bearing potential (FCBP): should use effective contraception during treatment with teclistamab and for 5 months after the last dose. FCBP should not breast feed during treatment with teclistamab and for 5 months after the last dose. Should a FCBP become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. The effects of iberdomide on the developing human fetus are unknown. However, IMiDs are known to be teratogenic. FCBP must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days prior to starting iberdomide, and again within 24 hours. FCBP must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control-one highly effective method and one additional effective method-at the same time, at least 28 days before starting iberdomide, while taking iberdomide, and for 28 days following discontinuation from the study. Examples of highly effective methods are intrauterine device, hormonal contraceptives, tubal ligation, or partner's vasectomy. Examples of barrier method are male condom, diaphragm, or cervical cap. FCBP must also agree to ongoing pregnancy testing. Men must practice complete abstinence or agree to use a condom during sexual contact with FCBP while participating in the study, during dose interruptions, and for at least 28 days following discontinuation from the study, even if he has undergone a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risk of fetal exposure
-
Men must agree to abstain from donating and semen or sperm while taking iberdomide, during dose interruptions, and for at least 28 days after the last dose of iberdomide. FCBP must agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period
-
All patients must agree to abstain from donating blood products while taking iberdomide and for at least 28 days after the last dose of iberdomide
-
Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study subjects
-
Willingness to adhere to the study visit schedule and other protocol requirements and provide mandatory blood and bone marrow specimens for correlative research
-
Willingness to return to the enrolling institution for follow-up
Exclusion Criteria:
- Patients who have active plasma cell leukemia, active amyloid light chain (AL) (primary) amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, myeloma protein, and skin changes), and Waldenstrom macroglobulinemia are ineligible
- If a patient develops recurrent/refractory (R/R) disease while receiving the most recent line of therapy, there is no need for a washout period
- Patients who have had prior anti-BCMA directed bispecific antibody (BsAb) therapy exposure (prior treatment with anti-BCMA directed antibody drug conjugate, anti-BCMA-directed chimeric antigen receptor [CAR] T cell therapy, and prior non-BCMA-targeting BsAb are permitted)
- Patients who have had prior treatment with a cereblon E3 ligase modulator, including mezigdomide, iberdomide, and CFT7455 (all currently in clinical development)
- Patients who received plasmapheresis ≤ 7 days prior to registration
- Patients who received a prior allogeneic SCT. Autologous SCT is allowed
- Patients who received a live or live-attenuated vaccine ≤ 30 days prior to registration. Patients are allowed to receive a coronavirus disease 2019 (COVID-19) vaccine at any timepoint during protocol treatment
- Systemic active infection requiring treatment
- Any unresolved toxicity ≥ grade 2 from previous treatment except for alopecia or peripheral neuropathy up to grade 2
- Patients who have had any major surgery ≤ 4 weeks prior to registration
- Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make this protocol unreasonably hazardous
- Patients with evidence of active mucosal or internal bleeding
- Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Stable chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if participant otherwise meets entry criteria
- Patients with known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to teclistamab or iberdomide, or any of the components of the study treatment
- Patients who are taking any anticancer therapy other than hormonal therapy (for prostrate or breast cancer) and palliative radiotherapy (defined as radiation to ≤ 3 sites of active multiple myeloma)
- Patients who require immunosuppressive medications including, but not limited to, systemic corticosteroids at doses exceeding 10 mg/day of prednisone or equivalent. Use of immunosuppressive medications for the management of iberdomide-related adverse events (AEs) or in subjects with contrast allergies is acceptable. In addition, use of inhaled, topical, intranasal corticosteroids or local steroid injection (e.g., intra-articular injection) is permitted. Temporary use of corticosteroids for concurrent illnesses (e.g., food allergies, computed tomography [CT] scan contrast hypersensitivity, pneumonia, etc.) are acceptable
- Patients who require medications that are strong inhibitors or inducers of CYP3A4/5
- Patients who are receiving any other investigational agents
- Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous
- Pregnant women are excluded from this study because iberdomide is a thalidomide analog and thalidomide is a known human teratogen. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with iberdomide, breastfeeding should be discontinued if the mother is treated with iberdomide. These potential risks may also apply to other agents used in this study
- Patients who are unable or unwilling to undergo protocol required thromboembolism prophylaxis are excluded
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Treatment (iberdomide, teclistamab)
Patients receive teclistamab SC on days 1, 4, 7, 15 and 22 for cycle 1 and days 1, 8, 15 and 22 for remaining cycles. Patients also receive iberdomide PO QD on days 1-21 for cycle 2 and beyond. Cycles repeat every 28 days for up to 4 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood and urine sample collection, bone marrow aspiration and biopsy and PET/CT or PET/MR throughout the trial. |
Undergo bone marrow aspiration and biopsy Undergo bone marrow aspiration and biopsy
Otros nombres:
Undergo blood and urine sample collection
Otros nombres:
Undergo PET/CT
Otros nombres:
Given PO
Otros nombres:
Undergo PET/MR
Otros nombres:
Undergo PET/CT or PET/MR
Otros nombres:
Given SC
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recommended phase 2 dose (RP2D) of iberdomide when combined with teclistamab
Periodo de tiempo: At 28 days
|
The RP2D will be defined as the pharmacologically optimal dose of iberdomide that can be combined with teclistamab and will be selected based on all available pharmacokinetic, pharmacodynamic, target engagement, efficacy, safety and tolerability data. |
At 28 days
|
|
Maximum tolerated dose (MTD) of iberdomide when combined with teclistamab
Periodo de tiempo: At 28 days
|
The MTD will be is defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 8 new patients). |
At 28 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of adverse events (AEs)
Periodo de tiempo: Up to 4 weeks after last dose of study treatment
|
AEs will be described and graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The maximum grade for each type of AE will be recorded for each patient, and frequency tables will be reviewed to determine patterns. The relationship of the AEs to the study treatment will be taken into consideration. |
Up to 4 weeks after last dose of study treatment
|
|
Overall response rate (ORR)
Periodo de tiempo: Up to 2 years after last dose of study treatment
|
The ORR will be estimated by the total number of patients who achieve a stringent complete response, complete response, very good partial response, or partial response divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true overall response rate will be calculated. |
Up to 2 years after last dose of study treatment
|
|
Minimal residual disease (MRD) negativity
Periodo de tiempo: Up to 2 years after last dose of study treatment
|
MRD negativity will be summarized descriptively at each specified timepoint. |
Up to 2 years after last dose of study treatment
|
|
Progression-free survival (PFS)
Periodo de tiempo: From registration to the earliest date of documentation of disease progression or death due to any cause, assessed up to 2 years after last dose of study treatment
|
The distribution of PFS will be estimated using the method of Kaplan-Meier. |
From registration to the earliest date of documentation of disease progression or death due to any cause, assessed up to 2 years after last dose of study treatment
|
|
Time to progression
Periodo de tiempo: From registration to the earliest date of documentation of disease progression, assessed up to 2 years after last dose of study treatment
|
The distribution of time to progression will be estimated using the method of Kaplan-Meier. |
From registration to the earliest date of documentation of disease progression, assessed up to 2 years after last dose of study treatment
|
|
Duration of response (DOR)
Periodo de tiempo: From earliest documentation of disease response to disease progression, assessed up to 2 years after last dose of study treatment
|
The distribution of DOR will be estimated using the method of Kaplan-Meier. |
From earliest documentation of disease response to disease progression, assessed up to 2 years after last dose of study treatment
|
|
Overall survival (OS)
Periodo de tiempo: From registration to death due to any cause, assessed up to 2 years after last dose of study treatment
|
The distribution of OS will be estimated using the method of Kaplan-Meier. |
From registration to death due to any cause, assessed up to 2 years after last dose of study treatment
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Tumor immune microenvironment
Periodo de tiempo: Up to 2 years after last dose of study treatment
|
Flow cytometry will be utilized to assess the tumor immune microenvironment in the bone marrow and peripheral blood at baseline and during active treatment at specified time points. Values over time will be summarized graphically and descriptively. Paired sample approaches (Wilcoxon signed rank test) will be used to assess differences over time. The relationship between changes over time in each measure with response outcome measures will be explored using Wilcoxon's rank sum test. |
Up to 2 years after last dose of study treatment
|
|
Soluble B-cell maturation antigen levels
Periodo de tiempo: At baseline
|
Values over time will be summarized graphically and descriptively. Paired sample approaches (Wilcoxon signed rank test) for these types of quantitative measures will be used to assess differences over time. The relationship between changes over time in each measure with response outcome measures will be explored using Wilcoxon's rank sum test. |
At baseline
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Ricardo D Parrondo, Dana-Farber - Harvard Cancer Center LAO
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Neoplasias
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Neoplasias De Células Plasmáticas
- Trastornos hemostáticos
- Paraproteinemias
- Trastornos de proteínas en sangre
- Trastornos hemorrágicos
- Enfermedades hemic y linfáticas
- Mieloma múltiple
- Técnicas de investigación
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Procedimientos quirúrgicos, operativo
- Técnicas citológicas
- Citodiagnóstico
- Técnicas de diagnóstico, quirúrgico
- Técnicas de química, analítica
- Análisis de espectro
- Biopsia
- Manejo de muestras
- Espectroscopía de resonancia magnética
- iberdomuro
Otros números de identificación del estudio
- NCI-2024-04754
- UM1CA186709 (Subvención/contrato del NIH de EE. UU.)
- 10620 (Otro identificador: CTEP)
- NCI-2024-04754 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- 10620 (Otro identificador: Dana-Farber - Harvard Cancer Center LAO)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .